Hot AI Mandate: US-based VC Interested in Early to Growth Stage Life Science Opportunities Focusing on the Midwestern US

A venture capital firm based in Missouri is looking to make growth-stage, equity investments in a variety of sectors, including the life sciences, typically in the $2M-$10M range. The firm prefers to lead rounds, but will also syndicate deals. The firm’s first fund closed late in 2015, and is targeting between 3 and 5 investments per year, focusing on the Midwestern United States. However, this includes all states except for those in the North East and those on the West Coast.

Within the Life Science space, the firm is primarily interested in data-driven, connected medical devices and diagnostics as well as any technology that improves drug adherence (mobile apps, devices, etc.). The firm has deep domain experience in IT and is therefore very interested in healthcare IT, such as enterprise software solutions. In addition, life science tools are also an area of interest, with one of the firm’s portfolio companies being a multiplex analyte detection platform. The firm is open to all sectors within the life sciences, with the exception of therapeutics, given the product is already FDA approved or is exempt from regulatory approval.

The firm prefers to work with experienced management teams and serial entrepreneurs, however the firm is open to working with first-time entrepreneurs. The firm prefers to lead rounds and requires a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Last Chance to Save $500 at RESI Boston

By Karen Deyo, Director of Investor Research, Israel BD, LSN

RESI returns for the first in-person event since January 2020! RESI Boston will take place at Westin Copley Place September 21-22, followed by a virtual-only day September 23. Super Early Bird rates end this Friday, July 1, so make sure to sign up and save on the lowest price available!

RESI Boston will have two days of in-person partnering, investor panels, educational workshops, and the Innovator’s Pitch Challenge, plus one dedicated day of virtual partnering. LSN is committed to bringing back essential face-to-face meetings, sessions, and valuable networking, while still enabling attendees to take part virtually if they are unable to travel. The last couple years have taught us a lot about the importance of accessibility in partnering, and we look forward to an event that combines the best of the important virtual connections and the in-person events we’ve missed.

Sign up today to save $500 off the full registration price!

Register-now-button-new

RESI-Boston-2022-Banner - new - 1100px

Free Summer Webinars for Fall Fundraising Success

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

Are you looking to raise funding and ready to capitalize on the return to in-person partnering events this fall? Life Science Nation (LSN) is offering a series of free webinars to help prepare your fundraising strategy for the busy fall conference season and beyond. Register below for these complimentary sessions:

July 7 | 2 PM EDT – Maximizing the Power of Your Pitch

Showcasing your company at events like the Innovator’s Pitch Challenge is an excellent opportunity to get visibility with investors and strategics. This workshop gives you tips from the application phase to the execution of the pitch and preparing for Q&A.

REGISTER HERE


July 13 | 12 PM EDT – Fundraising Bootcamp: It All Starts with the Story

The most successful entrepreneurs are always the best storytellers. Finding a way to naturally formulate your company’s unique story and portraying this through multiple modalities whether it be a 1-minute elevator pitch or a 12-slide pitch deck is one of the most effective ways to get potential investors and partners on board with your value proposition. This bootcamp will cover the importance of entrepreneurial agency, finding your voice and developing a compelling narrative for the different players that will emerge along a deal chain, and language tools to refine your hook. Investors always bet on the team, not just the technology, and if every member of your startup can tell any strategic partner a consistent story of your company and technology, you are on the right track to building successful relationships.

REGISTER HERE


July 20 | 1 PM EDT – Supporting Tech Hub Startups at RESI

This workshop is designed for tech hub organizations ranging from accelerators, incubators, non-profits, universities, tech transfer offices, and regional organizations who set up their early-stage life science startup constituents for success with their entrepreneurship and fundraising journey. It will showcase the tools and resources that LSN makes available for Tech Hubs to help their startup constituents who’ve raised less than $2M expand outreach from Regional to Global, build a target list of investors, and more.

REGISTER HERE


July 26 | 11 AM EDT – Fundraising Bootcamp: Branding Your Company from Seed to Series B

Many companies have great science and a compelling project to tell investors about, but don’t have the right tools to communicate effectively. What are the elements of marketing collateral needed to efficiently fundraise in the early stages? This webinar will dive into this important subject and help you to build a powerful marketing collateral for your fundraise.

REGISTER HERE


August 3 | 11 AM EDT – Maximizing the Power of Your Pitch

Showcasing your company at events like the Innovator’s Pitch Challenge is an excellent opportunity to get visibility with investors and strategics. This workshop gives you tips from the application phase to the execution of the pitch and preparing for Q&A.

REGISTER HERE


August 17 | 1 PM EDT – Keys to Successful Partnering

Partnering events like the RESI conference series are a fundamental part of fundraising. They present a great opportunity to meet new potential investors and strategic partners but getting the meetings you want is competitive and difficult. What strategies have proven successful to get the most meetings? What can you do to stand out and have a better chance of catching the attention of investors? This webinar will address these and other important aspects of partnering.

REGISTER HERE

RESI-Boston-2022-Banner - new - 1100px

What to Know When Preparing to Pitch

By Rory McCann, Director of Marketing, Conference Producer, LSN

The RESI Boston Innovator’s Pitch Challenge is now accepting applications! RESI is a leader in connecting early-stage companies with capital and licensing partners, but it’s the founders that present and pitch their way to success. Whether a first-time founder or a veteran, pitching can be daunting, but knowing how to speak to investors can give a founder an edge over a competing company. We’ve compiled a brief list of what-to-knows to help founders prepare for a successful pitch:

  1. Know your audience. Who are you pitching to? What are their concerns and pain points that you can address? For instance, a VC may have different questions than an angel or family office. Additionally, are they specific to your sector or technology? Understanding their background with your product will help you tailor how you present the information in a way that they comprehend.
  2. Know your format. Is this a warm introduction, cold call, or a pitch competition with limitations on how long you can speak for? Do you bring slides or share them ahead? Is it in-person or some virtual platform you need prior experience with? Knowing the format of the pitch is valuable because it saves precious time and shows investors that you are prepared.
  3. Know your presentation. Make sure you are comfortable with the points you’re hitting and the amount of time you plan to spend on each point. We recommend that pitching companies touch on their product or tech, team, company model, existing traction, market landscape, go-to-market strategy, and of course, the raise ask and how it’s to be used. Practice these points so you are confident in your presentation and comfortable fielding questions.

Want to put these tools to the test? Join us September 21-22 for the onsite Innovator’s Pitch Challenge at RESI Boston. Applications are accepted on a rolling basis, so get yours in soon!

RESI-Boston-2022-Banner - new - 1100px

Hot Investor Mandate: USA-Based Healthcare Company Seeks to In-License and Acquire Clinical Therapeutic Assets to Create New Subsidiaries

A healthcare company headquartered in the US with multiple offices globally has expanded to multiple subsidiaries that focus on different indications of unmet need. The firm is currently seeking promising assets to license and acquire, to supplement their existing asset portfolio and continue to expand to new disease areas. The firm is open to global opportunities.

The firm is only interested in therapeutics opportunities and is generally open to all indications and modalities. The firm has a preference for clinical stage assets, but may consider pre-clinical assets on occasion.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Asia-Based VC Firm Focuses on Medtech and Digital Health Investment Opportunities That Are Synergistic With Firm’s Investment and Hospital Network

A Venture Capital firm specializing in technologies, financials and healthcare industries is backed by an investment and hospital management team with more than 100 years and 80 years respectively of combined professional experiences.

The firm invests in three main sectors: Greater China’s healthcare reform opportunities, disruptive medical technologies & business models, and synergies with the firm’s domestic and foreign hospital & medical network.

The firm does not have management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Investment Firm is Most Interested in Therapeutics, But Invests Broadly Across All Life Science Sectors, Allocates Up to $10M Over Lifecycle

Life Sciences investment firm typically allocates up to $4M per initial investment. With follow-on allocations, the total investment can reach up to $10M per company. The firm takes a mid-to-long-term investment approach. The firm typically syndicates with major US venture capital firms. The firm is currently seeking new opportunities in the US, Canada, and Western Europe.

The firm puts 60% focus on therapeutics and 40% on medical devices, diagnostics and digital health. In therapeutics, the firm prefers late-stage assets with human proof of concept and blockbuster potential, while it also has a minor 20% interest in early-stage breakthrough bioengineering platforms with strong management teams. In medtech and digital health, the firm seeks to provide growth funding in technologically de-risked stories in final approval steps, launch and international marketing efforts. The firm considers both single assets and platform technologies. The firm’s investment strategy is strictly patient-centric. Lab equipment, medical services facilities and health tech, and biosimilars/generics/reformulations are not of interest.

The firm focuses on five key disease areas: oncology, autoimmune diseases, anti-infectives, CNS/pain, and women’s health. In oncology and autoimmune diseases, the firm seeks therapies with novel mechanisms of action, human data and signs of efficacy, and it also considers new generation molecular diagnostics technologies. In anti-infectives, the firm is considering early stage assets managed by serial entrepreneurs. In CNS, the firm seeks therapies with human proof-of-concept and a clear mechanism of action. In women’s health, the firm seeks a wide range of therapies and technologies at all stages, which predominantly help women give birth to healthy children.

The firm is looking for high-caliber serial entrepreneurs with an unmatched track-record of success and strong credibility. The firm does not typically take a board seat in the companies it invests in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.